Next generation sequencing

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: Discover an NGS-based AVA assay with enhanced sensitivity and specificity

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Webinar: Consolidate multiple assays into a single, comprehensive AVA test

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

Biosafety testing
#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Webinar: How can a single, comprehensive test enable broader viral detection?

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

Illustration of a virus
#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: Overcome the bottlenecks in AVA testing

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: The first GMP-validated AVA test using Oxford Nanopore sequencing

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

How ViruSure implemented an NGS-based AVA assay with enhanced sensitivity and specificity

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. Traditional AVA workflows require numerous parallel and sequential assays, often taking weeks to complete and contributing… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#Webinars

#Clinical trials #Next generation sequencing #Oncology #Sequencing

Bridging the clinical trials gap in cancer

Kathy Davy, President of Next-Generation Clinical Sequencing Division, Thermo Fisher Scientific, asks how clinical trials in cancer can be accelerated through the use of rapid next-generation sequencing (NGS) technology. Every cancer diagnosis marks the beginning of an urgent and often overwhelming journey for patients and their families. And in some… Read More

#Business & Investment #Cancer Research #Exclusive Content

#Cancer research #Cell profiling #Drug development #Financing #Next generation sequencing #One Biosciences

€15 million to advance clinical single cell profiling

One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Emulate #Gene expression #Gene therapy #Interview #Metabolomics #Multi-omics #Next generation sequencing #NGS #Omics #Organ-on-a-chip #Personalised medicine #Preclinical investigations #Spatial biology

Podcast: Cutting-edge tools shaping early-stage drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical… Read More

#News

Gene sequence
#Drug discovery #High throughput screening #Lab technology #Next generation sequencing #Roche

Will Roche’s new SBX technology revolutionise sequencing?

Roche has unveiled its new breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing.   According to the company, SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications. … Read More

#News #Trending News

#Automated liquid handling #Automation / robotics #Library screening #Next generation sequencing

Scientific Note: Optimise your NGS workflows

With the cost to sequence genomes declining dramatically, scientists and researchers are applying next generation sequencing (NGS) technology to new discoveries and clinical research applications at a rapidly expanding rate. These applications are driving the need for sample preparation workflows that prepare the DNA/RNA libraries prior to sequencing. A new… Read More

#News

#Automated liquid handling #Automation / robotics #Library screening #Next generation sequencing

Optimise your NGS workflows: 5-day path to sequencing

This Scientific Note explores: The benefits of vendor-qualified protocols, incl. reducing start-up process. The three levels of automated library preparation readiness. How fully vendor-qualified libraries enable sequencing in as few as five days. The importance of choosing providers with NGS expertise. Case studies comparing custom vs. vendor-qualified solutions deployment. Read More

#Resources

Next generation sequencing
#Advertorial #Drug discovery #Next generation sequencing

How fast nucleic acid quantification and purity assessment support NGS

This advertorial for BMG Labtech appeared in DDW Volume 26 – Issue 1, Winter 2024/25 Read the digital issue Next generation sequencing (NGS) is driving advances in the life sciences including the detection of disease-causing mutations. However, the downstream quantification of nucleic acids and purity assessment remain vital for success. Read More

#Exclusive Content

#Cancer research #Career #Chemical biology #Curve Therapeutics #Drug discovery #High throughput screening #Interview #Meet the Researcher #Next generation sequencing #Target identi

Meet the researcher: Ali Tavassoli

DDW’s Megan Thomas talks to Ali Tavassoli, Chief Scientific Officer of Curve Therapeutics and Professor of Chemical Biology at the University of Southampton, UK.  MT: Where do you work, and can you tell us what you’re working on at the moment?  AT: We spun Curve out of my academic… Read More

#Cancer Research #Exclusive Content

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

#Drug discovery #Interview #Next generation sequencing #NGS #Personalised medicine

The use-case for NGS

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is… Read More

#Exclusive Content